Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CoV-Hep Study: Anticoagulation in COVID-19 CVVHD
NCT04487990Completed
- Sponsor
- Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo
- Start
- Jun 2020
- Primary completion
- Mar 2021
- Modality
- Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of heparin in coronavirus disease 2019 (COVID-19) and acute kidney injury (AKI) (2 arms), sponsored by Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo. Primary endpoint: Clotted dialyzers at 72 hours. Started Jun 2020; status: completed.
02
Drugs
heparin
03
Conditions
coronavirus disease 2019 (COVID-19)acute kidney injury (AKI)
Beyond the preview
Go deeper on NCT04487990.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04487990.